Congratulations to Linnaeus for receiving clearance from the FDA for the company's investigational new drug application (IND) for LNS8801...
Read more
We are delighted to announce that Linnaeus Therapeutics, Inc. has closed a $12 million series B financing led by...
Read more
We are pleased to announce that Linnaeus Therapeutics is the latest company to join the Kairos portfolio. Linnaeus Therapeutics...
Read more